Results 71 to 80 of about 71,664 (187)

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

, 2019
Yiqun Han,1 Jiayu Wang,1 Weiming Liu,2 Peng Yuan,1 Qing Li,1 Pin Zhang,1 Fei Ma,1 Yang Luo,1 Ying Fan,1 Shanshan Chen,1 Ruigang Cai,1 Qiao Li,1 Binghe Xu11National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese ...
Cai R, Yuan P, Fan Y, Xu B, Han Y, Li Q, Luo Y, Chen S, Wang J, Ma F, Liu W, Zhang P   +11 more
core  

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations

, 2012
Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and
Alwin Jeyakumar, Tallal Younis
core   +1 more source

Established Prognostic Scores Predict Screen Failure But Not Post‐Enrollment Outcomes in Phase 1 Oncology Trials: A Single Centre Retrospective Audit

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Established Phase 1 prognostic scores predict screen failure but not post‐enrollment outcomes in a contemporary oncology cohort. Treatment‐related mortality was rare, supporting Phase 1 trials as a safe and reasonable option for appropriately selected patients.
Ortis Estacio, Eve Malsem, Georgia McGuiness, Megan Kesper, Hui Gan, Damien Kee, Sagun Parakh, Sarah Healy, Andrew Weickhardt   +8 more
wiley   +1 more source

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

, 2016
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The
Isabel Palacio-Vázquez, Yolanda Fernández-Pérez, Paula García-Teijido, Luisa Sánchez-Lorenzo, María Luque-Cabal   +4 more
core   +1 more source

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment

, 2020
Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast ...
Pan Yueyin, Jiang Xiaodong, Zhou Qiong, Dong Jie, Han Xinghua   +4 more
core   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Critical appraisal of trastuzumab in treatment of advanced stomach cancer

, 2011
Judith Meza-Junco, Heather-Jane Au, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice.
Michael B Sawyer, Judith Meza-Junco, Heather-Jane Au, null Michael B. Sawyer   +3 more
core   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source